Pharma major Lupin has reported its performance for the second quarter, which ended September 30, 2012. The unaudited results were announced at the Board of Directors meeting, which was held in Mumbai.
Net sales grew by 29 per cent to Rs 22,393 million during Q2 FY 2012-13, up from Rs 17,417 million (Q2 FY 2011-12). Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) grew by 28 per cent to Rs 5,203 million during Q2 FY 2012-13, up from Rs 4,057 million (Q2 FY 2011-12).
Profit Before Tax (PBT) grew by 27 per cent to Rs 4,412 million during Q2 FY 2012-13, up from Rs 3,468 million (Q2 FY 2011-12). Net profits grew by 9 per cent to Rs 2,905 million during Q2 FY 2012-13, up from Rs 2,669 million.
Dr Kamal K Sharma, Managing Director, Lupin, said, “We have had a record first half, driven by strong operating performance and sustained growth across all our business segments. Our growth momentum continues.”
EP News Bureau
- Advertisement -
